CSL Limited (OTCMKTS:CSLLY) Short Interest Down 98.5% in March

CSL Limited (OTCMKTS:CSLLY - Get Free Report) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 300 shares, a decrease of 98.5% from the February 28th total of 20,000 shares. Based on an average daily trading volume, of 134,500 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company's shares are short sold.

CSL Trading Down 0.5 %

CSLLY traded down $0.42 during midday trading on Friday, reaching $78.95. 101,058 shares of the company were exchanged, compared to its average volume of 87,300. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97. The stock's 50-day simple moving average is $82.30 and its 200 day simple moving average is $89.53. CSL has a one year low of $77.37 and a one year high of $109.00.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of CSL to a "strong-buy" rating in a report on Thursday, January 16th.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.